SAN DIEGO, CA / February 19, 2014 / ACCESSWIRE / Earth Dragon Resources, Inc. (OTC: EARH) today announced that it has completed the acquisition of Plasmagenix, Inc., a privately-held company and leader in the regenerative medicine industry. This acquisition was made by exchanging 13,800,000 shares of EARH common stock.
Plasmagenix, Inc. is now a wholly-owned subsidiary. PlasmaGenix is a biologics company located in Inglewood, California. Their three lead products, PlasmaNeu, PlasmaGen and PlasmaPro, have been used for over a decade to treat neuropathy associated with HIV and Diabetes, chronic non-healing wounds as well as acute and chronic musculoskeletal injuries.
Plasmagenix’s mission is to develop regenerative therapeutics derived from the patient’s own blood, commercialize them and facilitate access to those that suffer from chronic pain, non healing wounds and debilitating neurologic conditions both domestically and internationally.By completing this acquisition both management teams will focus on executing the business plan and combining forces to create a solid management infrastructure. Their perspective websites will be updated shortly to reflect the current direction of the company.
Earth Dragon Resources, Inc will be filing an 8k in the coming days.
Mike Johnson, CEO of Earth Dragon Resources, Inc. states, “We are excited about the future. Going forward, all our efforts will be directed to supporting Plasmagenix and we will update shareholders shortly on future developments.”
About Earth Dragon Resources, Inc.: Earth Dragon Resources, Inc. identifies opportunities globally. Earth Dragon Resources, Inc. primary focus is to identify, perform due diligence, structure and fund opportunities that have potential to enhance shareholder value.
About PlasmaGenix, Inc.:PlasmaGenix is a biologics company located in Inglewood, California. With more than three decades of clinical experience and research, PlasmaGenix is poised to be a major leader in the field of regenerative medicine by strategically addressing the needs of people that suffer from chronic neuropathic pain, chronic non-healing wounds as well as musculoskeletal injuries.
The mission of PlasmaGenix is to develop regenerative therapeutics derived from a patient’s own blood and facilitate access to treatment, particularly in high-risk populations both domestically and internationally. It’s three lead commercial products have been used to treat chronic pain, sports-related injuries, non-healing wounds as well as debilitating neurological conditions such as peripheral neuropathy associated with HIV and diabetes, muscular sclerosis and Charcot-Marie-Tooth disease.
The company is dedicated to developing and commercializing additional regenerative therapeutics. To date, the technology that Plasmagenix has exclusive rights to has successfully treated over 10,000 patients.
Disclaimer:The press release may include certain statements that are not descriptions of historical facts but are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking terminology such as "may," "expects," "believes," "anticipates," "intends," "projects," or similar terms, variations of such terms or the negative of such terms. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All of such assumptions are inherently subject to significant economic and competitive uncertainties and contingencies beyond our control and upon assumptions with respect to the future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectation and actual results may vary (perhaps materially) from certain of the results anticipated herein.
J. Michael JohnsonPresident and CEOOffice: 877-865-2283Email: [email protected]
Earth Dragon Resources, Inc.7660-H Fay Ave, Suite 312La Jolla, CA. 92037